03-05-2025News

HEUKING advises Dutch lead investor on investment in Munich AI and MedTech start-up hema.to in seed extension financing round

hema.to GmbH, an innovative deeptech AI and Medtech company, has successfully completed a seed extension financing round. The Company is transforming cytometry and immune medicine through end-to-end cloud-based software. Its clinical-grade AI software enables early and accurate diagnosis of blood cancers and immune diseases, paving the way for personalized treatments based on each patient’s unique immune system.

The company now successfully completed the seed extension round with investors such as LUMO Labs BV from the Netherlands (lead investor), BayernKapital, HTGF and Ealia Capital (Multy Family Office from Switzerland). Altogether hema.to received a EUR 3.6 million investment.

The newly raised funds will be used to refine product-market-fit in their first segment of blood cancer diagnostics, including additional European certification, and for clinical studies, expansion into diagnosis of broader immune disorders, and scaling commercial deployment.

“At hema.to we like to say that we want to ‘make your blood speak’”, says Karsten Miermans, hema.to’s CEO and co-founder. “Every 3rd person suffers from a life-altering immune disease at some point in their life. Blood data holds the key to the immune system, but at present life-threatening illnesses like leukaemia or lymphoma, can be overlooked in blood analysis – even when the data that indicates otherwise is right there. Through the AI models on our platform, we pull this data to the surface to get every patient an accurate diagnosis and treatment as early as possible. This is how we save lives.”

Amidst rising sample volumes and workforce shortages in Europe’s busiest clinical labs, cytometry teams typically need 20 minutes per patient sample, concentrating on complex, high-dimensional blood data. Fatigue, rising workloads, and limited staffing add to the risk of missed or delayed diagnosis.

“Through our investments in emerging technologies in Digital Health and Medtech, we want to improve the quality of life of patients and professionals and relieve the ever-increasing strain on public healthcare”, saysSven Bakkes, Founding Partner of LUMO Labs. “We are very happy to welcome hema.to into our portfolio. Their AI-powered platform scans raw cytometry files in seconds, detecting more diseases than human analysts can and soon also at earlier stages. For busy clinicians, that means a fraction of the manual analysis time. For patients, it can be the difference between a missed pathology and a life-saving early intervention.”

hema.to is headquartered in Munich and has 22 full-time employees across Germany, Portugal, Spain, Poland and Belgium.

The lead investor was legally supported by Dr. Patrick Müller (HEUKING Partner, Venture Capital DUS) and Roman Ettl-Steger (HEUKING Partner, VC MUC). HEUKING regularly advises start-ups as well as VC investors in various VC financing rounds.